Ralph Kern
Company: BrainStorm Cell Therapeutics
Job title: President & Chief Medical Officer
Seminars:
Chair Led Q&A 10:25 am
day: Day One
Opening Presentation: Treating Alzheimer’s Disease as a Heterogenous Disease 9:00 am
Reclassifying Alzheimer’s Disease based on Molecular Mechanisms Based on Targets Refining & Subtyping Alzheimer’s Disease to Stratify Patients for Drug Development & Optimize Treatment Utilising imaging & Fluid biomarkers to identify subtypes of Alzheimer’s Disease Utilizing a range of metrics to identify subtypes of Alzheimer’s Disease into different subcomponents. Determining the co-pathology of Alzheimer’s DiseaseRead more
day: Day One